Inventor
Yan Wang
Inventor
San Francisco, CA, US
Overview
Patents· 102 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides15%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations14%
C12NMicroorganisms or enzymes12%
A61KPreparations for medical, dental or toiletry purposes12%
C07DHeterocyclic compounds9%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms8%
C12YEnzymes6%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture6%
C07CAcyclic or carbocyclic compounds4%
Y02PClimate change mitigation technologies in the production or processing of goods3%
PatentTitleYear
10,787,694Methods and compositions for improving efficiency of nucleic acids amplification reactions202010,774,139ANGPTL8-binding agents and methods of use thereof202010,697,022PIK3CA novel mutations detection for diagnosis of acquired cetuximab resistance in metastatic colorectal cancer patients202010,683,551Detecting methylation in a subpopulation of genomic DNA202010,617,734STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof202010,577,593Compositions with polymerase activity202010,532,056Therapeutic compositions, combinations, and methods of use202010,533,068Polyurethanes, articles and coatings prepared therefrom and methods of making the same202010,526,320Pyrrolidine derivatives as PPAR agonists202010,513,563Method for uses of proinsulin transferrin fusion proteins as prodrugs201910,351,831Fusion polymerases201910,301,675Compositions and methods for reducing inhibition of RT-PCR201910,174,119Binding proteins and methods of use thereof201910,106,651PEEK/NANO-HA composites for SLS and preparation methods thereof201810,072,285RNA amplification methods201810,066,218Nucleic acid modifying enzymes20189,994,887Methods and compositions for improving efficiency of nucleic acids amplification reactions20189,968,616Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening20189,840,697'Fusion polymerases'20179,822,211'Polyurethanes, articles and coatings prepared therefrom and methods of making the same'20179,708,598'Methods of using improved polymerases'20179,688,969'Compositions with polymerase activity'20179,655,909'Personalized medicine for the prediction of therapy targeting the hedgehog pathway'20179,615,596'Protein products and methods for making the same'20179,598,527'Polyurethanes, articles and coatings prepared therefrom and methods of making the same'20179,518,295'High-throughput sequencing method for methylated DNA and use thereof'20169,493,824'Universal reference dye for quantitative amplification'20169,453,208'Nucleic acid modifying enzymes'20169,243,242'Methods of making di-tagged DNA libraries from DNA or RNA using double-tagged oligonucleotides'20169,200,318'Reduced inhibition of one-step RT-PCR'20159,145,550'Compositions with polymerase activity'20159,139,873'Methods of using improved polymerases'20159,073,974'RGD-containing cyclic peptides'20158,927,566'Norepinephrine and selective serotonin receptor blocker and use thereof'20158,900,846'Nucleic acid modifying enzymes'20148,895,283'Nucleic acid modifying enzymes'20148,877,949'Furo[3,2-g]chromene compounds and uses thereof'20148,859,205'Methods and compositions for improving efficiency of nucleic acids amplification reactions'20148,835,592'Polyurethanes, articles and coatings prepared therefrom and methods of making the same'20148,722,585'Methods of making di-tagged DNA libraries from DNA or RNA using double-tagged oligonucleotides'20148,652,821'Stabilized protease-containing solutions for purifying RNA-free DNA'20148,614,194'Anionic cell penetrating peptide and its use for intracellular delivery'20138,535,925'Modified DNase compositions and methods of use thereof'20138,476,045'Methods of using improved polymerases'20138,470,297'FDG-pet evaluation of Ewing\'s sarcoma sensitivity'20138,470,573'Hybrid polymerases having the ability to produce long amplicons'20138,445,249'Sso7-polymerase conjugate proteins'20138,426,431'Substituted 2-aminoacetamides and the use thereof'20138,426,132'Quantitative amplification with a labeled probe and 3′ to 5′ exonuclease activity'20138,415,129'Nucleic acid modifying enzymes'20138,367,376'Compositions with polymerase activity'20138,338,094'Reduced inhibition of one-step RT-PCR'20128,324,165'Compositions for treating arthritis comprising HG1023575 polypeptide'20128,232,078'Methods of using improved polymerases'20128,207,286'Methods for preparing polyurethanes'20128,173,779'Neutralizing human anti-IGFR antibody'20128,168,588'Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions'20128,114,872'Triazolyl aminopyrimidine compounds'20128,101,628'Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer'20128,063,035'Triazolyl aminopyrimidine compounds'20118,063,212'Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer'20118,017,735'Anti-IGFR1 antibody therapeutic combinations'20117,919,296'Nucleic acid modifying enzymes'20117,872,127'Substituted 2-aminoacetamides and the use thereof'20117,851,181'Neutralizing human anti-IGFR antibody'20107,847,068'Neutralizing human anti-IGFR antibody'20107,811,562'Biomarkers for pre-selection of patients for anti-IGF1R therapy'20107,670,808'Nucleic acid modifying enzymes'20107,667,021'Neutralizing human anti-IGFR antibody'20107,666,645'Sso7-polymerase conjugate proteins'20107,652,006'Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof'20107,560,260'Compositions with polymerase activity'20097,541,170'Nucleic acid modifying enzymes'20097,541,465'Substituted 2-aminoacetamides and the use thereof'20097,511,056'TGF-β inhibitors'20097,507,762'Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof'20097,445,898'Quantitative amplification with a labeled probe and 3′ to 5′ exonuclease activity'20087,405,299'Compounds as pharmaceutical agents'20087,368,445'Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms'20087,361,351'Method for sensitizing bovine mammary cells to respond to LPS'20087,332,592'Isolated recombinant bovine soluble CD14 polypeptide, rbosCD14'20087,303,752'Hookworm vaccine'20077,217,796'Neutralizing human anti-IGFR antibody'20077,163,790'Parallel polymorphism scoring by amplification and error correction'20077,091,210'Substituted 2-aminoacetamides and the use thereof'20066,984,503'Use of recombinant bovine CD14 in the treatment and prevention of coliform mastitis in dairy cows'20066,906,203'Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof'20056,716,818'Caspase inhibitors and the use thereof'20046,696,442'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'20046,638,947'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'20036,627,424'Nucleic acid modifying enzymes'20036,620,782'Substituted 2-aminobenzamide caspase inhibitors and the use thereof'20036,613,803'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'20036,500,825'Substituted 2-aminoacetamides and the use thereof'20026,495,522'Substituted alpha-hydroxy acid caspase inhibitors and the use thereof'20026,479,484'Substituted 2-aminoacetamides and the use thereof'20026,465,472'Substituted quinazolines and analogs and use thereof'20026,462,041'Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis'20026,458,843'Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof'20026,355,618'Caspase inhibitors and the use thereof'20026,153,591'Dipeptide caspase inhibitors and the use thereof'20005,891,871'Substituted 2,3-benzodiazepin-4-ones and the use thereof'1999Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2000–2009Patents assigned to CYTOVIA INC (8)· patent assignee history
2000–2016Based in San Diego, CA, US· patent location history
2002–2010Patents assigned to EURO CELTIQUE SA (7)· patent assignee history
2003–2020Based in San Francisco, CA, US· patent location history
2007–2020Patents assigned to BIO RAD LABORATORIES (31)· patent assignee history
2007–2011Based in Scotch Plains, NJ, US· patent location history
2008–2012Patents assigned to LILLY CO ELI (7)· patent assignee history
2008–2012Based in Carmel, IN, US· patent location history
2011–2019Patents assigned to WANG YAN (29)· patent assignee history
2012–2020Based in Seven Fields, PA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BIO RAD LABORATORIES | 31 | 2007–2020 |
| WANG YANself | 29 | 2011–2019 |
| CYTOVIA INC | 8 | 2000–2009 |
| EURO CELTIQUE SA | 7 | 2002–2010 |
| LILLY CO ELI | 7 | 2008–2012 |
Locations
| Location | Patents | Span |
|---|---|---|
| San Francisco, California, US | 37 | 2003–2020 |
| San Diego, California, US | 20 | 2000–2016 |
| Carmel, IN, US | 7 | 2008–2012 |
| Scotch Plains, New Jersey, US | 6 | 2007–2011 |
| Seven Fields, Pennsylvania, US | 5 | 2012–2020 |